摘要
目的:分析华蟾素胶囊与注射用吡柔比星联合应用于晚期乳腺癌治疗的临床效果和应用价值。方法:以2020年1月-2021年2月临沭县人民医院收治的108例晚期乳腺癌患者为研究对象,按照随机数字抽样分为参照组和研究组,各54例。参照组使用注射用吡柔比星进行静脉注射治疗,研究组采用静脉注射吡柔比星联合口服华蟾素胶囊进行治疗。比较两组患者治疗前后的生活质量评分、生存率和复发率情况、疼痛缓解率及临床疗效。结果:研究组的客观缓解率和临床控制率高于参照组,研究组生活质量评分改善程度高于参照组,参照组患者复发率高于研究组,参照组生存率低于研究组,差异均有统计学意义(P<0.05)。研究组治疗后的疼痛缓解率高于参照组,比较差异有统计学意义(P<0.01)。结论:注射用吡柔比星与华蟾素胶囊联合应用于晚期乳腺癌患者的治疗效果较为确切,治疗后患者的疼痛情况得到有效缓解,生活质量得到显著改善,生存率明显提高,复发率低。
Objective:To analyze the clinical effect and application value of Cinobufacine Capsule combined with Pirubicin for Injection in the treatment of advanced breast cancer.Methods:A total of 108 patients with advanced breast cancer admitted to Linshu People's Hospital from January 2020 to February 2021 were selected as the study subjects.According to random number sampling,they were divided into the reference group and the research group,with 54 cases in each group.The reference group received intravenous Pirubicin for Injection and the research group received intravenous Pirubicin for Injection combined with oral Cinobufacine Capsule.The changes of quality of life score,survival rate and recurrence rate,pain relief rate and clinical efficacy were compared between the two groups before and after treatment.Results:The objective response rate and clinical control rate of the research group were higher than those of the reference group,the improvement degree of quality of life scores in the study group was higher than that in the reference group,the recurrence rate of patients in the reference group was higher than that in the research group,and the survival rate in the reference group was lower than that in the research group,with statistical significance(P<0.05).After treatment,the pain relief rate of the research group was higher than that of the reference group,and the difference was statistically significant(P<0.01).Conclusion:The combined application of Pirubicin for Injection and Cinobufacine Capsule in the treatment of patients with advanced breast cancer has a more accurate effect.After treatment,the pain of patients has been effectively alleviated,the quality of life has been significantly improved,the survival rate has been significantly increased,and the recurrence rate is low.
作者
于恒旺
Yu Heng-wang(Department of Oncology,Linshu People's Hospital,Linyi 276700,Shandong Province,China)
出处
《中国社区医师》
2022年第6期37-39,共3页
Chinese Community Doctors
关键词
乳腺癌
吡柔比星
华蟾素胶囊
Breast cancer
Pirubicin
Cinobufacine Capsule